165 related articles for article (PubMed ID: 17105865)
1. Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis.
Rajakulendran S; Gadsby K; Allen D; O'Reilly S; Deighton C
Ann Rheum Dis; 2006 Dec; 65(12):1678-9. PubMed ID: 17105865
[No Abstract] [Full Text] [Related]
2. Unstable diabetes in a patient receiving anti-TNF-alpha for rheumatoid arthritis.
Boulton JG; Bourne JT
Rheumatology (Oxford); 2007 Jan; 46(1):178-9. PubMed ID: 16998233
[No Abstract] [Full Text] [Related]
3. Management of rheumatoid arthritis.
Handa R
Natl Med J India; 2004; 17(3):143-51. PubMed ID: 15253402
[TBL] [Abstract][Full Text] [Related]
4. Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures.
Wendling D; Balblanc JC; Brousse A; Lohse A; Lehuede G; Garbuio P; Toussirot E; Auge B; Jacques D
Ann Rheum Dis; 2005 Sep; 64(9):1378-9. PubMed ID: 16100348
[No Abstract] [Full Text] [Related]
5. Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery.
Talwalkar SC; Grennan DM; Gray J; Johnson P; Hayton MJ
Ann Rheum Dis; 2005 Apr; 64(4):650-1. PubMed ID: 15769927
[No Abstract] [Full Text] [Related]
6. Cautionary note: a possible association between oral squamous cell carcinoma and tumor necrosis factor antagonists; need for oral screening.
Rahman N; Healy C; Flint SR; Stassen LF
J Clin Rheumatol; 2010 Jun; 16(4):197-9. PubMed ID: 20511984
[No Abstract] [Full Text] [Related]
7. Guillain-Barré syndrome in a patient receiving anti-tumour necrosis factor alpha for rheumatoid arthritis: a case report and discussion of literature.
Silburn S; McIvor E; McEntegart A; Wilson H
Ann Rheum Dis; 2008 Apr; 67(4):575-6. PubMed ID: 18349168
[No Abstract] [Full Text] [Related]
8. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.
Geborek P; Bladström A; Turesson C; Gulfe A; Petersson IF; Saxne T; Olsson H; Jacobsson LT
Ann Rheum Dis; 2005 May; 64(5):699-703. PubMed ID: 15695534
[TBL] [Abstract][Full Text] [Related]
9. Neutropenia in patients receiving anti-tumor necrosis factor therapy.
Hastings R; Ding T; Butt S; Gadsby K; Zhang W; Moots RJ; Deighton C
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):764-9. PubMed ID: 20535786
[TBL] [Abstract][Full Text] [Related]
10. Drugs for rheumatoid arthritis.
Treat Guidel Med Lett; 2012 May; 10(117):37-44; quiz 2 p following 44. PubMed ID: 22538522
[No Abstract] [Full Text] [Related]
11. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
Baslund B; Bendtzen K
Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
[TBL] [Abstract][Full Text] [Related]
12. Primary nasal tuberculosis during anti-tumour necrosis factor alpha treatment of a patient with rheumatoid arthritis.
Ribeiro S; Ferreira B; Duarte R; Almeida I; Vasconcelos C
Scand J Infect Dis; 2013 Dec; 45(12):957-60. PubMed ID: 23957541
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.
Favalli EG; Arreghini M; Arnoldi C; Panni B; Marchesoni A; Tosi S; Pontikaki I
Arthritis Rheum; 2004 Apr; 51(2):301-2. PubMed ID: 15077278
[No Abstract] [Full Text] [Related]
14. Biologic therapy for early rheumatoid arthritis: the latest evidence.
Castro-Rueda H; Kavanaugh A
Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
[TBL] [Abstract][Full Text] [Related]
15. Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost.
Pressman Lovinger S
JAMA; 2003 Jun; 289(24):3229-30. PubMed ID: 12824197
[No Abstract] [Full Text] [Related]
16. Infectious complications of biologic agents.
Martin-Mola E; Balsa A
Rheum Dis Clin North Am; 2009 Feb; 35(1):183-99. PubMed ID: 19481004
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
Higashida J; Wun T; Schmidt S; Naguwa SM; Tuscano JM
J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study.
den Broeder AA; Creemers MC; Fransen J; de Jong E; de Rooij DJ; Wymenga A; de Waal-Malefijt M; van den Hoogen FH
J Rheumatol; 2007 Apr; 34(4):689-95. PubMed ID: 17117492
[TBL] [Abstract][Full Text] [Related]
19. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.
Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Ann Rheum Dis; 2005 Oct; 64(10):1421-6. PubMed ID: 15829572
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab-induced neutropenia in a patient with rheumatoid arthritis.
Ottaviani S; Cerf-Payrastre I; Kemiche F; Pertuiset E
Joint Bone Spine; 2009 May; 76(3):312-3. PubMed ID: 19289296
[No Abstract] [Full Text] [Related]
[Next] [New Search]
